IRLAB Therapeutics AB (publ) (IRLAB-A) - Total Liabilities

Latest as of December 2025: Skr107.49 Million SEK ≈ $11.57 Million USD

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has total liabilities worth Skr107.49 Million SEK (≈ $11.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IRLAB-A asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

IRLAB Therapeutics AB (publ) - Total Liabilities Trend (2013–2025)

This chart illustrates how IRLAB Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Competitors by Total Liabilities

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
PCCS Group Bhd KLSE:6068	Malaysia	RM162.58 Million
Bambuser AB ST:BUSER	Sweden	Skr47.62 Million
NYESA VALOS CO.EO 001 F:7NY0	Germany	€30.88 Million
Hank Payments Corp V:HANK	Canada	CA$12.55 Million
Sejoong Co. Ltd KQ:039310	Korea	₩15.13 Billion
New York City REIT Inc NYSE:NYC	USA	$380.40 Million
Klaria Pharma Holding AB ST:KLAR	Sweden	Skr50.62 Million
Vereinigte Filzfabriken AG MU:VFF	Germany	€6.93 Million

Liability Composition Analysis (2013–2025)

This chart breaks down IRLAB Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of IRLAB Therapeutics AB (publ) to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.76	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.78	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how IRLAB Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for IRLAB Therapeutics AB (publ) (2013–2025)

The table below shows the annual total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr107.49 Million ≈ $11.57 Million	+3.78%
2024-12-31	Skr103.58 Million ≈ $11.15 Million	+68.81%
2023-12-31	Skr61.36 Million ≈ $6.60 Million	+87.50%
2022-12-31	Skr32.72 Million ≈ $3.52 Million	-55.15%
2021-12-31	Skr72.97 Million ≈ $7.85 Million	+228.86%
2020-12-31	Skr22.19 Million ≈ $2.39 Million	-15.44%
2019-12-31	Skr26.24 Million ≈ $2.82 Million	+110.59%
2018-12-31	Skr12.46 Million ≈ $1.34 Million	+56.32%
2017-12-31	Skr7.97 Million ≈ $857.81K	-13.57%
2016-12-31	Skr9.22 Million ≈ $992.54K	+1.74%
2015-12-31	Skr9.06 Million ≈ $975.54K	-49.23%
2014-12-31	Skr17.86 Million ≈ $1.92 Million	+254971.43%
2013-12-31	Skr7.00K ≈ $753.31	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$15.76 Million

Skr146.47 Million SEK

Market Cap Rank

#25934 Global

#530 in Sweden

Share Price

Skr1.73

Change (1 day)

-0.46%

52-Week Range

Skr1.20 - Skr3.04

All Time High

Skr104.95